Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
D 1.17 -9.30% -0.12
LCTX closed down 9.3 percent on Monday, March 18, 2024, on 85 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Crossed Above 200 DMA Bullish -9.30%
New Uptrend Bullish -9.30%
180 Bullish Setup Bullish Swing Setup -9.30%
Pocket Pivot Bullish Swing Setup -9.30%
Wide Bands Range Expansion -9.30%
200 DMA Resistance Bearish 0.86%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 10 hours ago
Down 10% about 10 hours ago
60 Minute Opening Range Breakdown about 13 hours ago
Gap Down Partially Closed about 14 hours ago
Down 1 ATR about 14 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lineage Cell Therapeutics, Inc. Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Immunotherapy Stem Cell Cell Therapy Non Small Cell Lung Cancer Drug Delivery Human Diseases Degenerative Disease Osteoarthritis Regenerative Medicine Advanced Therapy Lineage Cell Therapeutics Stem Cell Therapy Dry Age Related Macular Degeneration

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.569
52 Week Low 0.8414
Average Volume 813,700
200-Day Moving Average 1.21
50-Day Moving Average 1.10
20-Day Moving Average 1.14
10-Day Moving Average 1.20
Average True Range 0.11
RSI (14) 52.15
ADX 26.2
+DI 24.03
-DI 10.99
Chandelier Exit (Long, 3 ATRs) 1.12
Chandelier Exit (Short, 3 ATRs) 1.35
Upper Bollinger Bands 1.31
Lower Bollinger Band 0.96
Percent B (%b) 0.6
BandWidth 30.45
MACD Line 0.04
MACD Signal Line 0.03
MACD Histogram 0.0075
Fundamentals Value
Market Cap 220.52 Million
Num Shares 188 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -9.00
Price-to-Sales 23.21
Price-to-Book 2.99
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.32
Resistance 3 (R3) 1.33 1.30 1.30
Resistance 2 (R2) 1.30 1.26 1.29 1.29
Resistance 1 (R1) 1.23 1.23 1.22 1.22 1.28
Pivot Point 1.20 1.20 1.19 1.19 1.20
Support 1 (S1) 1.13 1.16 1.12 1.12 1.06
Support 2 (S2) 1.10 1.13 1.09 1.05
Support 3 (S3) 1.03 1.10 1.05
Support 4 (S4) 1.02